Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 1/2012

01.07.2012

Pre PCI hospital antithrombotic therapy for ST elevation myocardial infarction: striving for consensus

verfasst von: S. Michael Gharacholou, Brenda J. Larson, Christian C. Zuver, Ryan J. Wubben, Giorgio Gimelli, Amish N. Raval

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Strong evidence exists in favor of rapid transfer of a patient suffering an ST-elevation myocardial infarction (STEMI) to the nearest hospital with primary percutaneous coronary intervention (PCI) capability, assuming the time from first medical contact to balloon inflation can be achieved in less than 90 min. In many areas, PCI hospitals have successfully collaborated with regional non-PCI hospitals to provide primary PCI for STEMI; however, significant variations exist in how these programs are executed. For example, the pre PCI hospital administration of antithrombotic agents by emergency medical personnel can include aspirin, clopidogrel, unfractionated heparin, low molecular weight heparin, partial or full dose fibrinolytics or combinations thereof. There is little consensus on the optimal cocktail, dose and route of administration. Standardizing the pre PCI antithrombotic regimen across hospital systems may be one approach to improve timely administration of these therapies, and potentially improve STEMI outcomes.
Literatur
1.
Zurück zum Zitat Antman EM, Anbe DT, Armstrong PW et al (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110:e82–292PubMedCrossRef Antman EM, Anbe DT, Armstrong PW et al (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110:e82–292PubMedCrossRef
2.
Zurück zum Zitat Jacobs AK, Antman EM, Faxon DP, Gregory T, Solis P (2007) Development of systems of care for ST-elevation myocardial infarction patients: executive summary. Circulation 116:217–230PubMedCrossRef Jacobs AK, Antman EM, Faxon DP, Gregory T, Solis P (2007) Development of systems of care for ST-elevation myocardial infarction patients: executive summary. Circulation 116:217–230PubMedCrossRef
3.
Zurück zum Zitat Gharacholou SM, Alexander KP, Chen AY et al (2010) Implications and reasons for the lack of use of reperfusion therapy in patients with ST-segment elevation myocardial infarction: findings from the CRUSADE initiative. Am Heart J 159:757–763PubMedCrossRef Gharacholou SM, Alexander KP, Chen AY et al (2010) Implications and reasons for the lack of use of reperfusion therapy in patients with ST-segment elevation myocardial infarction: findings from the CRUSADE initiative. Am Heart J 159:757–763PubMedCrossRef
4.
Zurück zum Zitat Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez-Sendon J (2002) Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 359:373–377PubMedCrossRef Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez-Sendon J (2002) Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 359:373–377PubMedCrossRef
5.
Zurück zum Zitat Grzybowski M, Clements EA, Parsons L et al (2003) Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis. JAMA 290:1891–1898PubMedCrossRef Grzybowski M, Clements EA, Parsons L et al (2003) Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis. JAMA 290:1891–1898PubMedCrossRef
6.
Zurück zum Zitat Boden WE, Eagle K, Granger CB (2007) Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options. J Am Coll Cardiol 50:917–929PubMedCrossRef Boden WE, Eagle K, Granger CB (2007) Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options. J Am Coll Cardiol 50:917–929PubMedCrossRef
7.
Zurück zum Zitat Jacobs AK, Antman EM, Ellrodt G et al (2006) Recommendation to develop strategies to increase the number of ST-segment-elevation myocardial infarction patients with timely access to primary percutaneous coronary intervention. Circulation 113:2152–2163PubMedCrossRef Jacobs AK, Antman EM, Ellrodt G et al (2006) Recommendation to develop strategies to increase the number of ST-segment-elevation myocardial infarction patients with timely access to primary percutaneous coronary intervention. Circulation 113:2152–2163PubMedCrossRef
8.
Zurück zum Zitat Goodman SG, Menon V, Cannon CP, Steg G, Ohman EM, Harrington RA (2008) Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:708S–775SPubMedCrossRef Goodman SG, Menon V, Cannon CP, Steg G, Ohman EM, Harrington RA (2008) Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:708S–775SPubMedCrossRef
9.
Zurück zum Zitat Van de Werf F, Bax J, Betriu A et al (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 29:2909–2945PubMedCrossRef Van de Werf F, Bax J, Betriu A et al (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 29:2909–2945PubMedCrossRef
10.
Zurück zum Zitat Cantor WJ, Fitchett D, Borgundvaag B et al (2009) Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 360:2705–2718PubMedCrossRef Cantor WJ, Fitchett D, Borgundvaag B et al (2009) Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 360:2705–2718PubMedCrossRef
12.
Zurück zum Zitat Eisenberg MJ, Topal EJ (1996) Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction. Arch Intern Med 156:1506–1510PubMedCrossRef Eisenberg MJ, Topal EJ (1996) Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction. Arch Intern Med 156:1506–1510PubMedCrossRef
13.
Zurück zum Zitat ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2:349–360 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2:349–360
14.
Zurück zum Zitat Heestermans T, van ’t Hof AW, ten Berg JM et al (2010) The golden hour of prehospital reperfusion with triple antiplatelet therapy: a sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy. Am Heart J 160:1079–1084PubMedCrossRef Heestermans T, van ’t Hof AW, ten Berg JM et al (2010) The golden hour of prehospital reperfusion with triple antiplatelet therapy: a sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy. Am Heart J 160:1079–1084PubMedCrossRef
15.
Zurück zum Zitat Berger JS, Stebbins A, Granger CB et al (2008) Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. Circulation 117:192–199PubMedCrossRef Berger JS, Stebbins A, Granger CB et al (2008) Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. Circulation 117:192–199PubMedCrossRef
16.
Zurück zum Zitat Mehta SR, Bassand JP, Chrolavicius S et al (2010) Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 363:930–942PubMedCrossRef Mehta SR, Bassand JP, Chrolavicius S et al (2010) Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 363:930–942PubMedCrossRef
17.
Zurück zum Zitat Mehta SR, Tanguay JF, Eikelboom JW et al (2010) Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376:1233–1243PubMedCrossRef Mehta SR, Tanguay JF, Eikelboom JW et al (2010) Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376:1233–1243PubMedCrossRef
18.
Zurück zum Zitat Pollack CV Jr, Antman EM, Hollander JE (2008) 2007 focused update to the ACC/AHA guidelines for the management of patients with ST-segment elevation myocardial infarction: implications for emergency department practice. Ann Emerg Med 52(344–355):e341 Pollack CV Jr, Antman EM, Hollander JE (2008) 2007 focused update to the ACC/AHA guidelines for the management of patients with ST-segment elevation myocardial infarction: implications for emergency department practice. Ann Emerg Med 52(344–355):e341
19.
Zurück zum Zitat Mehta SR, Yusuf S, Peters RJ et al (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527–533PubMedCrossRef Mehta SR, Yusuf S, Peters RJ et al (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527–533PubMedCrossRef
20.
Zurück zum Zitat Leon MB, Baim DS, Popma JJ et al (1998) A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339:1665–1671PubMedCrossRef Leon MB, Baim DS, Popma JJ et al (1998) A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339:1665–1671PubMedCrossRef
21.
Zurück zum Zitat Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502PubMedCrossRef Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502PubMedCrossRef
22.
Zurück zum Zitat Chen ZM, Jiang LX, Chen YP et al (2005) Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366:1607–1621PubMedCrossRef Chen ZM, Jiang LX, Chen YP et al (2005) Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366:1607–1621PubMedCrossRef
23.
Zurück zum Zitat Sabatine MS, Cannon CP, Gibson CM et al (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352:1179–1189PubMedCrossRef Sabatine MS, Cannon CP, Gibson CM et al (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352:1179–1189PubMedCrossRef
24.
Zurück zum Zitat Scirica BM, Sabatine MS, Morrow DA et al (2006) The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. J Am Coll Cardiol 48:37–42PubMedCrossRef Scirica BM, Sabatine MS, Morrow DA et al (2006) The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. J Am Coll Cardiol 48:37–42PubMedCrossRef
25.
Zurück zum Zitat Sabatine MS, Cannon CP, Gibson CM et al (2005) Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294:1224–1232PubMedCrossRef Sabatine MS, Cannon CP, Gibson CM et al (2005) Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294:1224–1232PubMedCrossRef
26.
Zurück zum Zitat Antman EM, Hand M, Armstrong PW et al (2008) 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 117:296–329PubMedCrossRef Antman EM, Hand M, Armstrong PW et al (2008) 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 117:296–329PubMedCrossRef
27.
Zurück zum Zitat Kushner FG, Hand M, Smith SC Jr et al (2009) 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 54:2205–2241PubMedCrossRef Kushner FG, Hand M, Smith SC Jr et al (2009) 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 54:2205–2241PubMedCrossRef
28.
Zurück zum Zitat Levine GN, Bates ER, Blankenship JC et al (2011) ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58:e44–122PubMedCrossRef Levine GN, Bates ER, Blankenship JC et al (2011) ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58:e44–122PubMedCrossRef
29.
Zurück zum Zitat Mangiacapra F, Muller O, Ntalianis A et al (2010) Comparison of 600 versus 300-mg clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol 106:1208–1211PubMedCrossRef Mangiacapra F, Muller O, Ntalianis A et al (2010) Comparison of 600 versus 300-mg clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol 106:1208–1211PubMedCrossRef
30.
Zurück zum Zitat Alexander KP, Chen AY, Roe MT et al (2005) Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294:3108–3116PubMedCrossRef Alexander KP, Chen AY, Roe MT et al (2005) Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294:3108–3116PubMedCrossRef
31.
Zurück zum Zitat Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119:2553–2560PubMedCrossRef Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119:2553–2560PubMedCrossRef
32.
Zurück zum Zitat Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O’Gara PT, Stein CM (2010) ACCF/AHA Clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 122:537–557PubMedCrossRef Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O’Gara PT, Stein CM (2010) ACCF/AHA Clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 122:537–557PubMedCrossRef
33.
Zurück zum Zitat Desai NR, Mega JL, Jiang S, Cannon CP, Sabatine MS (2009) Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 53:1273–1278PubMedCrossRef Desai NR, Mega JL, Jiang S, Cannon CP, Sabatine MS (2009) Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 53:1273–1278PubMedCrossRef
34.
Zurück zum Zitat Gilard M, Arnaud B, Cornily JC et al (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51:256–260PubMedCrossRef Gilard M, Arnaud B, Cornily JC et al (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51:256–260PubMedCrossRef
35.
Zurück zum Zitat Shuldiner AR, O’Connell JR, Bliden KP et al (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849–857PubMedCrossRef Shuldiner AR, O’Connell JR, Bliden KP et al (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849–857PubMedCrossRef
36.
Zurück zum Zitat Small DS, Farid NA, Payne CD et al (2010) Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pharmacokinet 49:777–798PubMedCrossRef Small DS, Farid NA, Payne CD et al (2010) Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pharmacokinet 49:777–798PubMedCrossRef
37.
Zurück zum Zitat Farid NA, Smith RL, Gillespie TA et al (2007) The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 35:1096–1104PubMedCrossRef Farid NA, Smith RL, Gillespie TA et al (2007) The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 35:1096–1104PubMedCrossRef
38.
Zurück zum Zitat Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015PubMedCrossRef Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015PubMedCrossRef
39.
Zurück zum Zitat Serebruany VL (2011) Timing of thienopyridine loading and outcomes in the TRITON trial: the FDA Prasugrel Action Package outlook. Cardiovasc Revasc Med 12:94–98PubMedCrossRef Serebruany VL (2011) Timing of thienopyridine loading and outcomes in the TRITON trial: the FDA Prasugrel Action Package outlook. Cardiovasc Revasc Med 12:94–98PubMedCrossRef
40.
Zurück zum Zitat Bhatt DL (2007) Intensifying platelet inhibition—navigating between Scylla and Charybdis. N Engl J Med 357:2078–2081PubMedCrossRef Bhatt DL (2007) Intensifying platelet inhibition—navigating between Scylla and Charybdis. N Engl J Med 357:2078–2081PubMedCrossRef
41.
Zurück zum Zitat Teng R, Oliver S, Hayes MA, Butler K (2010) Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 38:1514–1521PubMedCrossRef Teng R, Oliver S, Hayes MA, Butler K (2010) Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 38:1514–1521PubMedCrossRef
42.
Zurück zum Zitat Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057PubMedCrossRef Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057PubMedCrossRef
43.
Zurück zum Zitat Steg PG, James S, Harrington RA et al (2010) Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 122:2131–2141PubMedCrossRef Steg PG, James S, Harrington RA et al (2010) Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 122:2131–2141PubMedCrossRef
44.
Zurück zum Zitat Cannon CP (2000) Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials. Clin Cardiol 23(Suppl 6):VI-14–VI-17 Cannon CP (2000) Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials. Clin Cardiol 23(Suppl 6):VI-14–VI-17
45.
Zurück zum Zitat Ottani F, La Vecchia L, De Vita M, Catapano O, Tarantino F, Galvani M (2010) Comparison by meta-analysis of eptifibatide and tirofiban to abciximab in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 106(167–174):e161 Ottani F, La Vecchia L, De Vita M, Catapano O, Tarantino F, Galvani M (2010) Comparison by meta-analysis of eptifibatide and tirofiban to abciximab in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 106(167–174):e161
46.
Zurück zum Zitat Mehilli J, Kastrati A, Schulz S et al (2009) Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 119:1933–1940PubMedCrossRef Mehilli J, Kastrati A, Schulz S et al (2009) Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 119:1933–1940PubMedCrossRef
47.
Zurück zum Zitat Ellis SG, Tendera M, de Belder MA et al (2008) Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 358:2205–2217PubMedCrossRef Ellis SG, Tendera M, de Belder MA et al (2008) Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 358:2205–2217PubMedCrossRef
48.
Zurück zum Zitat Henry TD, Sharkey SW, Burke MN et al (2007) A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction. Circulation 116:721–728PubMedCrossRef Henry TD, Sharkey SW, Burke MN et al (2007) A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction. Circulation 116:721–728PubMedCrossRef
49.
Zurück zum Zitat Keeley EC, Boura JA, Grines CL (2006) Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 367:579–588PubMedCrossRef Keeley EC, Boura JA, Grines CL (2006) Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 367:579–588PubMedCrossRef
50.
Zurück zum Zitat Investigtors A-P (2006) Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 367:569–578CrossRef Investigtors A-P (2006) Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 367:569–578CrossRef
51.
Zurück zum Zitat Gharacholou SM, Lopes RD, Washam JB, Newby LK, James SK, Alexander JH (2010) Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician. J Thromb Thrombolysis 29:516–528PubMedCrossRef Gharacholou SM, Lopes RD, Washam JB, Newby LK, James SK, Alexander JH (2010) Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician. J Thromb Thrombolysis 29:516–528PubMedCrossRef
52.
Zurück zum Zitat Mahaffey KW, Granger CB, Collins R et al (1996) Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol 77:551–556PubMedCrossRef Mahaffey KW, Granger CB, Collins R et al (1996) Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol 77:551–556PubMedCrossRef
53.
Zurück zum Zitat Antman EM, Hand M, Armstrong PW et al (2008) 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 51:210–247PubMedCrossRef Antman EM, Hand M, Armstrong PW et al (2008) 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 51:210–247PubMedCrossRef
54.
Zurück zum Zitat Antman EM, Morrow DA, McCabe CH et al (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354:1477–1488PubMedCrossRef Antman EM, Morrow DA, McCabe CH et al (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354:1477–1488PubMedCrossRef
55.
Zurück zum Zitat Yusuf S, Mehta SR, Chrolavicius S et al (2006) Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295:1519–1530PubMedCrossRef Yusuf S, Mehta SR, Chrolavicius S et al (2006) Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295:1519–1530PubMedCrossRef
56.
Zurück zum Zitat Stone GW, Witzenbichler B, Guagliumi G et al (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358:2218–2230PubMedCrossRef Stone GW, Witzenbichler B, Guagliumi G et al (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358:2218–2230PubMedCrossRef
57.
Zurück zum Zitat Dangas GD, Mehran R, Nikolsky E et al (2011) Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis. J Am Coll Cardiol 57:2309–2316PubMedCrossRef Dangas GD, Mehran R, Nikolsky E et al (2011) Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis. J Am Coll Cardiol 57:2309–2316PubMedCrossRef
58.
Zurück zum Zitat Berger PB, Ellis SG, Holmes DR Jr et al (1999) Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation 100:14–20PubMedCrossRef Berger PB, Ellis SG, Holmes DR Jr et al (1999) Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation 100:14–20PubMedCrossRef
59.
Zurück zum Zitat Jollis JG, Roettig ML, Aluko AO et al (2007) Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. JAMA 298:2371–2380PubMedCrossRef Jollis JG, Roettig ML, Aluko AO et al (2007) Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. JAMA 298:2371–2380PubMedCrossRef
60.
Zurück zum Zitat Ting HH, Rihal CS, Gersh BJ et al (2007) Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation 116:729–736PubMedCrossRef Ting HH, Rihal CS, Gersh BJ et al (2007) Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation 116:729–736PubMedCrossRef
61.
Zurück zum Zitat Aguirre FV, Varghese JJ, Kelley MP et al (2008) Rural interhospital transfer of ST-elevation myocardial infarction patients for percutaneous coronary revascularization: the Stat Heart Program. Circulation 117:1145–1152PubMedCrossRef Aguirre FV, Varghese JJ, Kelley MP et al (2008) Rural interhospital transfer of ST-elevation myocardial infarction patients for percutaneous coronary revascularization: the Stat Heart Program. Circulation 117:1145–1152PubMedCrossRef
62.
Zurück zum Zitat Blankenship JC, Haldis TA, Wood GC, Skelding KA, Scott T, Menapace FJ (2007) Rapid triage and transport of patients with ST-elevation myocardial infarction for percutaneous coronary intervention in a rural health system. Am J Cardiol 100:944–948PubMedCrossRef Blankenship JC, Haldis TA, Wood GC, Skelding KA, Scott T, Menapace FJ (2007) Rapid triage and transport of patients with ST-elevation myocardial infarction for percutaneous coronary intervention in a rural health system. Am J Cardiol 100:944–948PubMedCrossRef
63.
Zurück zum Zitat Andersen HR, Nielsen TT, Rasmussen K et al (2003) A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 349:733–742PubMedCrossRef Andersen HR, Nielsen TT, Rasmussen K et al (2003) A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 349:733–742PubMedCrossRef
64.
Zurück zum Zitat Chakrabarti A, Krumholz HM, Wang Y, Rumsfeld JS, Nallamothu BK (2008) Time-to-reperfusion in patients undergoing interhospital transfer for primary percutaneous coronary intervention in the U.S: an analysis of 2005 and 2006 data from the National Cardiovascular Data Registry. J Am Coll Cardiol 51:2442–2443PubMedCrossRef Chakrabarti A, Krumholz HM, Wang Y, Rumsfeld JS, Nallamothu BK (2008) Time-to-reperfusion in patients undergoing interhospital transfer for primary percutaneous coronary intervention in the U.S: an analysis of 2005 and 2006 data from the National Cardiovascular Data Registry. J Am Coll Cardiol 51:2442–2443PubMedCrossRef
65.
Zurück zum Zitat Blankenship JC, Scott TD, Skelding KA et al (2011) Door-to-balloon times under 90 min can be routinely achieved for patients transferred for ST-segment elevation myocardial infarction percutaneous coronary intervention in a rural setting. J Am Coll Cardiol 57:272–279PubMedCrossRef Blankenship JC, Scott TD, Skelding KA et al (2011) Door-to-balloon times under 90 min can be routinely achieved for patients transferred for ST-segment elevation myocardial infarction percutaneous coronary intervention in a rural setting. J Am Coll Cardiol 57:272–279PubMedCrossRef
Metadaten
Titel
Pre PCI hospital antithrombotic therapy for ST elevation myocardial infarction: striving for consensus
verfasst von
S. Michael Gharacholou
Brenda J. Larson
Christian C. Zuver
Ryan J. Wubben
Giorgio Gimelli
Amish N. Raval
Publikationsdatum
01.07.2012
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 1/2012
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-012-0744-4

Weitere Artikel der Ausgabe 1/2012

Journal of Thrombosis and Thrombolysis 1/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.